Camouflage and sabotage: tumor escape from the immune system (Q37882478)

24 August 2017

1 reference

title

Camouflage and sabotage: tumor escape from the immune system (English)

1 reference

24 August 2017

Isabel Poschke

1 reference

24 August 2017

Dimitrios Mougiakakos

series ordinal

1 reference

24 August 2017

Rolf Kiessling

series ordinal

1 reference

24 August 2017

publication date

6 April 2011

1 reference

Cancer Immunology, Immunotherapy

24 August 2017

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

1161-1171

1 reference

Anti-CTLA-4 antibody adjuvant therapy in melanoma

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Evidence for the involvement of a nuclear NF-kappa B inhibitor in global down-regulation of the major histocompatibility complex class I enhancer in adenovirus type 12-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

The E75 HER2/neu peptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Reversal of tumor-mediated immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Myeloid-derived suppressor cells: linking inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Regulatory T cells in immunologic self-tolerance and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Natural regulatory T cells: mechanisms of suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Oxidative stress and cancer: have we moved forward?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Oxidative stress and lymphocyte persistence: implications in immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Extracellular redox modulation by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Immune regulatory antibodies: are they the next advance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1012-8

10.1007/S00262-011-1012-8

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference